Talem Therapeutics is a wholly owned subsidiary of ImmunoPrecise Antibodies and is focused on the
discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/specialty diseases. Using the proprietary
antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies and U-Protein
Express (an IPA company), Talem aims to accelerate novel, therapeutic antibody treatments to the clinic through
strategic alliances and partners.
The demand for safe, therapeutic, monoclonal antibody candidates with more complex target product
profiles is driving a need for more robust discoveries. Talem was founded to expedite the high-powered discovery
and development of custom therapeutics produced as both internal assets as well as in response to partnership
requests with large pharma.
Partner with Talem Therapeutics
We partner to discover your therapeutic antibody. By collaborating with us, we offer interested partners the
use of our proprietary technologies to jointly discover and develop therapeutic antibodies against any target.
We involve you in the discovery process and provide lead candidates in a short amount of time.